Results 31 to 40 of about 234,095 (317)

Publicness, Organisational Characteristics and Performance [PDF]

, 2013
This paper reports an exploratory study utilising a publicness model in which the impact of ownership, funding and mode of control on performance is moderated by organisational characteristics such as goals, structure and management.
B.Bozeman, B.Bozeman, D. R.Dalton, G. A.Hodge, J. N.Baldwin, L.Donaldson, R. E.Ashworth, S.Kelman   +7 more
core   +1 more source

Physiological monitoring in the complex multimorbid heart failure patient - Conclusions. [PDF]

, 2019
Comorbidities are increasingly recognized as crucial components of the heart failure syndrome. Main specific challenges are polypharmacy, poor adherence to treatments, psychological aspects, and the need of monitoring after discharge.
Böhm, M, Coats, AJS, Kindermann, I, Rosano, G, Spoletini, I   +4 more
core   +1 more source

A Healthcare Failure Mode and Effect Analysis on the Safety of Secondary Infusions [PDF]

Proceedings of the Human Factors and Ergonomics Society Annual Meeting, 2012
Secondary infusions are a common and convenient method to administer intermittent infusion unattended through a single IV access using infusion pump technology. Previous studies have indicated that clinicians have a high frequency of committing operation errors while administering secondary infusions.
Rossini Ying Kwan Yue, Patricia Trbovich, Tony Easty   +2 more
openaire   +1 more source

Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes. [PDF]

, 2017
IntroductionThere are currently no guidelines for switching patients from oral risperidone to paliperidone palmitate (Invega Sustenna®). Furthermore, the paliperidone long-acting injectable (LAI) package insert does not recommend bridging with oral ...
Hsia, Stephanie L, Jackson, Elizabeth, Lacro, Jonathan P, Leckband, Susan G, Rao, Sanjai   +4 more
core   +2 more sources

Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program. [PDF]

, 2016
BackgroundPatient-reported outcome (PRO) measures can be used to support label claims if they adhere to US Food & Drug Administration guidance. The process of developing a new PRO measure is expensive and time-consuming.
Anatchkova, Milena, Chau, Dina, Malik, Fady I, Oko-Osi, Hafiz, Patrick, Donald L, Spertus, John, Teerlink, John R, von Maltzahn, Robyn, Wiklund, Ingela   +8 more
core   +1 more source

Addressing Health Insurance Deductions through an Interventional Study: the Case of a Large Central Hospital

Asia Pacific Journal of Health Management, 2016
Objective: A large proportion of hospitals’ private income is provided by insurance organisations. Hospitals in Iran face various problems in terms of insurance deductions from insurance organisations resulting from inefficient performance by both the ...
Erfan Kharazmi, Asiyeh Salehi, Neda Hashemi, Shekufe Ghaderi, Nahid Hatam   +4 more
doaj   +1 more source

Challenges experienced during pharmacy automation and robotics implementation in JCI accredited hospital in the Arabian Gulf area: FMEA analysis-qualitative approach

Saudi Pharmaceutical Journal, 2023
Background: Pharmacy automation and robotics implementation are essential aspects of healthcare facilities. It streamlines the medication dispensing process and significantly reduces medication errors.
May Hassan ElLithy, Omar Alsamani, Hager Salah, Francis Byron Opinion, Lamyaa Samir Abdelghani   +4 more
doaj   +1 more source

Comparative Ethics of Modern Payment Models

Voices in Bioethics, 2023
Photo by Marek Studzinski on Unsplash ABSTRACT Payment models directly impact the way patients experience care. Historically, payment model innovations have been examined mostly from economic, organizational, and public health lenses.
Jacob Riegler
doaj   +5 more sources

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]

, 2019
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...
Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V.   +155 more
core   +4 more sources

HEALTHCARE FAILURE MODE AND EFFECT ANALYSIS DESIGN FOR INDONESIA HOSPITAL LABORATORIES: A LITERATURE REVIEW

Jurnal Administrasi Kesehatan Indonesia, 2021
Background: Error rate in medical laboratories is very low. Only one error is identified every 330–1,000 events. The goal of laboratory services should outweigh patient safety in a well-structured manner. Healthcare Failure Mode and Effect Analysis (HFMEA) is a proactive preventive method for identifying and evaluating potential failure.Aims: This ...
Salsabila, Zhafirah, Masyitoh, Masyitoh, Sjaaf, Amal Chalik, Partakusuma, Lia Gardenia   +3 more
openaire   +4 more sources